Gene therapeutic DNA vector based on the gene therapeutic DNA vector VTvaf17, carrying the target gene selected from the group of SHH, CTNNB1, NOG, WNT7A genes to increase the expression level of these target genes, method for its preparation and use, Escherichia coli strain SCS110-AF / VTvaf17- SHH or Escherichia coli SCS110-AF / VTvaf17-CTNNB1 or Escherichia coli SCS110-AF / VTvaf17-NOG or Escherichia coli SCS110-AF / VTvaf17-WNT7A, carrying a gene therapy DNA vector, method for its production, industrial-scale production of gene therapy DNA of vector
The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. A gene therapy DNA vector based on the VTvaf17 gene therapy DNA vector is proposed that carries a target gene selected from the group of SHH, CTNNB1, NOG, WNT7A genes for the treatment of diseases characterized by impaired tissue regeneration, wound healing, growth, pigmentation and hair coloring, formation and maturation of hair follicles, processes of differentiation and growth of cells, leading to a decrease in the activity of hair follicles, including with allopecia, autoimmune diseases, hereditary and acquired pathological conditions thawing, and for accelerated healing of wounds, restoration of the hairline and the prevention and inhibition of alopecia. Moreover, the gene therapy DNA vector VTvafl7-SHH, or VTvaf 17 -CTNNB 1, or VTvaf17-NOG, or VTvaf17-WNT7A has the nucleotide sequence of SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4, respectively. Also provided are a method of producing said vector, the use of a vector, a strain of Escherichia coli carrying said vector, as well as a method of industrial production of said vector.
